- Reuters•4 days ago
Bristol-Myers Squibb Co (BMY.N) shares fell 11 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co Inc's (MRK.N) leading position in the burgeoning immuno-oncolgy field. Lung cancer is by far the biggest oncology market and a handful of companies have been battling to become dominant in initial, or first-line, treatment, and to provide much-needed combination therapies. Merck shares rose 3.6 percent to $62.53, while Bristol fell to $49.23.
- Accesswire•4 days ago
Upcoming AWS Coverage on AstraZeneca LONDON, UK / ACCESSWIRE / January 20, 2017 / Active Wall St. blog coverage looks at the headline from AbbVie Inc. (NYSE: ABBV ) as the Company announced on January ...
- Financial Times•5 days ago
GlaxoSmithKline has poached its new global head of pharmaceuticals from rival AstraZeneca, marking a change of guard at Britain's biggest drugmaker as it prepares for the arrival of its new chief executive. ...
AZN : Summary for Astrazeneca PLC Common Stock - Yahoo Finance
AstraZeneca PLC (AZN)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||26.65 - 27.12|
|52 Week Range||25.55 - 35.04|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||30.85|
|Dividend & Yield||0.90 (3.32%)|
|1y Target Est||N/A|